Glucagon-like peptide-1 receptor agonists improve kidney graft survival following kidney transplantation
Japan: In a study published in The Journal of Clinical Endocrinology & Metabolism, JCEM, researchers have addressed the crucial role of GLP-1 RAs in patients undergoing kidney transplant surgery.
Tetsuhiko Sato from the Division of Integrated Strategic Medicine, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital wrote this study entitled, “Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients with Type 2 Diabetes.”
Previous research has portrayed the potential of Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in improving native kidney function.
Elaborating further, researchers in this present study elucidated the possible protective effects of GLP-1 RAs on kidney graft function after successful kidney transplantation (KTX).
They included all KTX recipients (KTRs) with type 2 diabetes who were followed up from 1-month post-transplantation for 24 months or longer.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.